UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 579

Sortiert nach

Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn’s Disease: A Post Hoc Analysis From the CALM Study

Inflammatory bowel diseases, 2020-10, Vol.26 (10), p.1562-1571

2020

Link zum Volltext

Verfügbarkeit prüfen

Validation of a quantitative systems pharmacology model of calcium homeostasis using elagolix Phase 3 clinical trial data in women with endometriosis

Clinical and translational science, 2021-07, Vol.14 (4), p.1611-1619

2021

Link zum Volltext

Verfügbarkeit prüfen

Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients

Clinical pharmacokinetics, 2020-03, Vol.59 (3), p.311-326

2020

Link zum Volltext

Verfügbarkeit prüfen

Relationship Between Venetoclax Exposure and Undetectable Minimal Residual Disease Rates in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of Six Clinical Studies

HemaSphere, 2023-12, Vol.7 (12), p.e983-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn’s Disease: Analyses of Phase I and II Trials

Clinical pharmacokinetics, 2019-03, Vol.58 (3), p.375-387

2019

Link zum Volltext

Verfügbarkeit prüfen

Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I–III Clinical Trials

Clinical pharmacokinetics, 2019-10, Vol.58 (10), p.1309-1321

2019

Link zum Volltext

Verfügbarkeit prüfen

Exposure–Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis

Clinical pharmacokinetics, 2020-05, Vol.59 (5), p.575-589

2020

Link zum Volltext

Verfügbarkeit prüfen

Exposure–Response Relationships for Efficacy and Safety of Risankizumab in Phase II and III Trials in Psoriasis Patients

Clinical pharmacology and therapeutics, 2020-02, Vol.107 (2), p.378-387

2020

Link zum Volltext

Verfügbarkeit prüfen

Impact of Multiple Concomitant CYP3A Inhibitors on Venetoclax Pharmacokinetics: A PBPK and Population PK‐Informed Analysis

Journal of clinical pharmacology, 2023-01, Vol.63 (1), p.119-125

2023

Link zum Volltext

Verfügbarkeit prüfen

Pooled Population Pharmacokinetic Analyses of Venetoclax in Patients Across Indications and Healthy Subjects from Phase 1, 2, and 3 Clinical Trials

Journal of clinical pharmacology, 2023-08, Vol.63 (8), p.950-960

2023

Link zum Volltext

Verfügbarkeit prüfen

Industrial Perspective on the Benefits Realized From the FDA’s Model‐Informed Drug Development Paired Meeting Pilot Program

Clinical pharmacology and therapeutics, 2021-11, Vol.110 (5), p.1172-1175

2021

Link zum Volltext

Verfügbarkeit prüfen

Bioavailability Evaluation of Venetoclax Lower-Strength Tablets and Oral Powder Formulations to Establish Interchangeability with the 100 mg Tablet

Clinical drug investigation, 2022-08, Vol.42 (8), p.657-668

2022

Link zum Volltext

Verfügbarkeit prüfen

Population Pharmacokinetics and Exposure–Response Analyses for Risankizumab in Patients with Active Psoriatic Arthritis

Rheumatology and therapy., 2022-12, Vol.9 (6), p.1587-1603

2022

Link zum Volltext

Verfügbarkeit prüfen

Cedirogant Population Pharmacokinetics and Pharmacodynamic Analyses of Interleukin‐17A Inhibition in Two Phase 1 Studies in Healthy Participants and Participants with Moderate to Severe Psoriasis

Clinical pharmacology in drug development, 2024-05, Vol.13 (5), p.474-484

2024

Link zum Volltext

Verfügbarkeit prüfen

Physiological variables and molecular study of KLK2 and KLK3 among patient with benign prostatic hyperplasia

Alexandria journal of medicine, 2018-09, Vol.54 (3), p.203-206

2018

Link zum Volltext

Verfügbarkeit prüfen

Recovery of the Vulnerable Pemba flying fox Pteropus voeltzkowi: population and conservation status

Oryx, 2010-07, Vol.44 (3), p.416-423

2010

Link zum Volltext

Verfügbarkeit prüfen

Population Pharmacokinetic and Exposure–Response Modeling to Inform Risankizumab Dose Selection in Patients With Ulcerative Colitis

Clinical pharmacology and therapeutics, 2024-06

2024

Link zum Volltext

Verfügbarkeit prüfen

Associations of Epigenetic methylation with vitamin D receptor level in Iraqi Gestational diabetes mellitus patients

Maǧallat Markaz buhūt al-taqniyyat al-ahyāʼiyyat (Online), 2023-07, Vol.17 (2)

2023

Link zum Volltext

Verfügbarkeit prüfen

The risk of up normal values of two parameters obesity and vitamin D in incidence of coronavirus disease-19 among Iraqi patients

AIP Conference Proceedings, 2022, Vol.2394 (1)

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1257: Early blood uMRD correlates with improved PFS in patients with CLL

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.1257-1257

2022

Link zum Volltext

Verfügbarkeit prüfen

Identification of Novel miRNAs Involved in Cancer Progression and Metastasis in Clear Cell Renal Cell Carcinoma

Matematicheskai︠a︡ biologii︠a︡ i bioinformatika = Mathematical biology and bioinformatics, 2022-11, Vol.17 (2), p.338-359

2022

Link zum Volltext

Verfügbarkeit prüfen

The impact of ACE2 genetic polymorphisms (rs2106809 and rs2074192) on gender susceptibility to COVID-19 infection and recovery: A systematic review

Baghdad journal of biochemistry & applied biological sciences, 2021-09, Vol.2 (3), p.167-180

2021

Link zum Volltext

Verfügbarkeit prüfen

Acceptance of COVID-19 vaccine and associated factors among healthcare workers in Katsina state: a cross-sectional study in Northwest Nigeria

BMJ open, 2023-12, Vol.13 (12), p.e063281-e063281

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 579

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(472)
Mit Volltextzugriff
(533)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

4 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(314)
Life Sciences & Biomedicine
(231)
Humans
(122)
Female
(73)
Male
(68)
Technology
(60)
Adult
(37)
Engineering
(35)
Physical Sciences
(34)
Middle Aged
(32)
Pharmacology & Pharmacy
(32)
Animals
(31)
Original
(30)
Science & Technology - Other Topics
(28)
Aged
(22)
Biological And Medical Sciences
(22)
Medicine
(22)
Nigeria
(22)
Chemistry
(21)
Materials Science
(20)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(14)

Menü

Weitere Dienste

Einstellungen

Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn’s Disease: A Post Hoc Analysis From the CALM Study

Validation of a quantitative systems pharmacology model of calcium homeostasis using elagolix Phase 3 clinical trial data in women with endometriosis

Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients

Relationship Between Venetoclax Exposure and Undetectable Minimal Residual Disease Rates in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of Six Clinical Studies

Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn’s Disease: Analyses of Phase I and II Trials

Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I–III Clinical Trials

Sorafenib and everolimus in patients with advanced solid tumors and KRAS‐mutated NSCLC: A phase I trial with early pharmacodynamic FDG‐PET assessment

Exposure–Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis

Exposure–Response Relationships for Efficacy and Safety of Risankizumab in Phase II and III Trials in Psoriasis Patients

Impact of Multiple Concomitant CYP3A Inhibitors on Venetoclax Pharmacokinetics: A PBPK and Population PK‐Informed Analysis

Pooled Population Pharmacokinetic Analyses of Venetoclax in Patients Across Indications and Healthy Subjects from Phase 1, 2, and 3 Clinical Trials

Industrial Perspective on the Benefits Realized From the FDA’s Model‐Informed Drug Development Paired Meeting Pilot Program

Bioavailability Evaluation of Venetoclax Lower-Strength Tablets and Oral Powder Formulations to Establish Interchangeability with the 100 mg Tablet

Population Pharmacokinetics and Exposure–Response Analyses for Risankizumab in Patients with Active Psoriatic Arthritis

Expanding the Repertoire for "Large Small Molecules": Prodrug ABBV-167 Efficiently Converts to Venetoclax with Reduced Food Effect in Healthy Volunteers

Cedirogant Population Pharmacokinetics and Pharmacodynamic Analyses of Interleukin‐17A Inhibition in Two Phase 1 Studies in Healthy Participants and Participants with Moderate to Severe Psoriasis

Physiological variables and molecular study of KLK2 and KLK3 among patient with benign prostatic hyperplasia

Recovery of the Vulnerable Pemba flying fox Pteropus voeltzkowi: population and conservation status

Population Pharmacokinetic and Exposure–Response Modeling to Inform Risankizumab Dose Selection in Patients With Ulcerative Colitis

Associations of Epigenetic methylation with vitamin D receptor level in Iraqi Gestational diabetes mellitus patients

The risk of up normal values of two parameters obesity and vitamin D in incidence of coronavirus disease-19 among Iraqi patients

Abstract 1257: Early blood uMRD correlates with improved PFS in patients with CLL

Identification of Novel miRNAs Involved in Cancer Progression and Metastasis in Clear Cell Renal Cell Carcinoma

The impact of ACE2 genetic polymorphisms (rs2106809 and rs2074192) on gender susceptibility to COVID-19 infection and recovery: A systematic review

Acceptance of COVID-19 vaccine and associated factors among healthcare workers in Katsina state: a cross-sectional study in Northwest Nigeria

Suchergebnisse filtern